Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Editas Medicine, Inc.EDIT · Entity 5502 | Director | May 30, 2024 | June 03, 2024 |
| PAREXEL INTERNATIONAL CORPPRXL · Entity 172709 | Corp. VP & Interim CFO | December 07, 2016 | December 09, 2016 |
| PTC THERAPEUTICS, INC.PTCT · Entity 3803 | Director | January 02, 2026 | January 06, 2026 |
| Whitehawk Therapeutics, Inc.WHWK · Entity 6074 | Director | June 12, 2026 | June 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Editas Medicine, Inc.
Report date May 30, 2024 · Filed June 03, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.17 · Expires 2034-05-29 | Direct | 25,000 |
Reported balance
After 2024-05-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-05-30 · Grant · Acquired 25,000 · Balance 25,000 F1: This option was granted on May 30, 2024 and is scheduled to vest in full on May 30, 2025 |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on May 30, 2024 and is scheduled to vest in full on May 30, 2025
PAREXEL INTERNATIONAL CORP
Report date December 07, 2016 · Filed December 09, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,468 |
Reported balance
After 2016-12-07 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2016-12-07 · Grant · Acquired 2,348 · Balance 8,468 F1: Shares of restricted stock awarded pursuant to PAREXEL International Corporation 2015 Stock Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares of restricted stock awarded pursuant to PAREXEL International Corporation 2015 Stock Incentive Plan.
PTC THERAPEUTICS, INC.
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,666 |
Ending reported balance
After 2026-01-05 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-01-02 · Grant · Acquired 4,000 · Balance 10,666 F1: Restricted stock units granted on January 2, 2026 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 2, 2026 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 2, 2027. Row 2 · 2026-01-05 · Exercise / conversion · Acquired 734 · Balance 11,400 F2: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025. Row 3 · 2026-01-05 · Sale · Disposed 734 · Balance 10,666 F2: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $76.74 · Expires 2036-01-01 | Direct | 3,475 |
Reported balance
After 2026-01-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-01-02 · Grant · Acquired 3,475 · Balance 3,475 F3: This option was granted on January 2, 2026 and vests over one year in twelve equal monthly installments, commencing on February 2, 2026. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $46.54 · Expires 2035-01-02 | Direct | 0 |
Reported balance
After 2026-01-05 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-01-05 · Exercise / conversion · Disposed 734 · Balance 0 F2: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025. F4: Currently exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units granted on January 2, 2026 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 2, 2026 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 2, 2027.
F2: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025.
F3: This option was granted on January 2, 2026 and vests over one year in twelve equal monthly installments, commencing on February 2, 2026.
F4: Currently exercisable.
Whitehawk Therapeutics, Inc.
Report date June 12, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.16 · Expires 2036-06-12 | Direct | 38,040 |
Reported balance
After 2026-06-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-12 · Grant · Acquired 38,040 · Balance 38,040 F1: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 12, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 12, 2026.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CONSTELLATION PHARMACEUTICALS INC
Report date July 15, 2021 · Filed July 19, 2021
Section 16 reporting ended · disclosed 2021-07-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.06 | Direct | 0 |
Reported balance
After 2021-07-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-07-15 · Disposition to issuer · Disposed 60,000 · Balance 0 F1: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.50 | Direct | 0 |
Reported balance
After 2021-07-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-07-15 · Disposition to issuer · Disposed 37,527 · Balance 0 F1: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.76 | Direct | 0 |
Reported balance
After 2021-07-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-07-15 · Disposition to issuer · Disposed 73,428 · Balance 0 F1: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.04 | Direct | 0 |
Reported balance
After 2021-07-15 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-07-15 · Disposition to issuer · Disposed 11,777 · Balance 0 F1: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.60 | Direct | 0 |
Reported balance
After 2021-07-15 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-07-15 · Disposition to issuer · Disposed 17,666 · Balance 0 F1: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.61 | Direct | 0 |
Reported balance
After 2021-07-15 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-07-15 · Disposition to issuer · Disposed 80,971 · Balance 0 F1: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.50 | Direct | 0 |
Reported balance
After 2021-07-15 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-07-15 · Disposition to issuer · Disposed 66,950 · Balance 0 F1: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 12, 2020 Filed Feb 14, 2020 17:09 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | SaleCommon Stock | 1,103 | $35.02 | $38,623.97 |
DisclosureSEC source: 0001562180-20-001251 · primarydocument.xml · nonDerivative · entry 2 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $35.00 to $35.04. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 17:09 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionCommon Stock | 1,103 | $8.04 | $8,868.12 |
DisclosureSEC source: 0001562180-20-001251 · primarydocument.xml · nonDerivative · entry 1 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,103 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 17:36 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionStock Option (right to buy) · Derivative | 7,212 | $0.00 Strike: $7.60 | $0.00 |
DisclosureSEC source: 0001562180-20-001123 · primarydocument.xml · derivative · entry 9 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,200 Underlying: Common Stock · 7,212 shares Expires 2028-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option was granted on March 6, 2018. The shares underlying the option are scheduled to vest in equal quarterly installments through December 6, 2021. Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 17:36 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionStock Option (right to buy) · Derivative | 1,430 | $0.00 Strike: $8.04 | $0.00 |
DisclosureSEC source: 0001562180-20-001123 · primarydocument.xml · derivative · entry 8 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,266 Underlying: Common Stock · 1,430 shares Expires 2028-04-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted on April 23, 2018. The shares underlying the option are scheduled to vest in equal quarterly installments through October 23, 2021. Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 17:36 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | SaleCommon Stock | 1,430 | $35.04 | $50,107.20 |
DisclosureSEC source: 0001562180-20-001123 · primarydocument.xml · nonDerivative · entry 6 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: This transaction was executed in multiple trades at prices ranging from $35.00 to $35.095. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 17:36 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionCommon Stock | 1,430 | $8.04 | $11,497.20 |
DisclosureSEC source: 0001562180-20-001123 · primarydocument.xml · nonDerivative · entry 5 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,430 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 17:36 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | SaleCommon Stock | 7,212 | $35.04 | $252,708.48 |
DisclosureSEC source: 0001562180-20-001123 · primarydocument.xml · nonDerivative · entry 4 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: This transaction was executed in multiple trades at prices ranging from $35.00 to $35.095. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 17:36 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionCommon Stock | 7,212 | $7.60 | $54,811.20 |
DisclosureSEC source: 0001562180-20-001123 · primarydocument.xml · nonDerivative · entry 3 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,212 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 17:36 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionStock Option (right to buy) · Derivative | 200 | $0.00 Strike: $7.60 | $0.00 |
DisclosureSEC source: 0001562180-20-001123 · primarydocument.xml · derivative · entry 7 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,412 Underlying: Common Stock · 200 shares Expires 2028-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option was granted on March 6, 2018. The shares underlying the option are scheduled to vest in equal quarterly installments through December 6, 2021. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 17:36 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | SaleCommon Stock | 200 | $35.00 | $7,000.00 |
DisclosureSEC source: 0001562180-20-001123 · primarydocument.xml · nonDerivative · entry 2 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 17:36 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionCommon Stock | 200 | $7.60 | $1,520.00 |
DisclosureSEC source: 0001562180-20-001123 · primarydocument.xml · nonDerivative · entry 1 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 21:43 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right To Buy) · Derivative | 10,000 | $0.00 Strike: $51.16 | $0.00 |
DisclosureSEC source: 0001070081-20-000051 · wf-form4_158050696729754.xml · derivative · entry 2 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-01-28 F2 · derivative.exercise_date: This option was granted on January 29, 2020 and vests over one year in twelve equal monthly installments, commencing on February 29, 2020. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 21:43 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 1,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001070081-20-000051 · wf-form4_158050696729754.xml · nonDerivative · entry 1 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,650 F1 · shares: Restricted stock units ("RSUs") granted on January 29, 2020 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 10, 2020 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 29, 2021. Read SEC document |
| November 06, 2019 Filed Nov 8, 2019 17:01 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionStock Option (right to buy) · Derivative | 9,084 | $0.00 Strike: $7.60 | $0.00 |
DisclosureSEC source: 0001562180-19-005413 · primarydocument.xml · derivative · entry 11 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,612 Underlying: Common Stock · 9,084 shares Expires 2028-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: This option was granted on March 6, 2018. The shares underlying the option are scheduled to vest in equal quarterly installments through March 6, 2022. Read SEC document |
| November 06, 2019 Filed Nov 8, 2019 17:01 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionStock Option (right to buy) · Derivative | 56,542 | $0.00 Strike: $6.61 | $0.00 |
DisclosureSEC source: 0001562180-19-005413 · primarydocument.xml · derivative · entry 10 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,793 Underlying: Common Stock · 56,542 shares Expires 2027-12-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: This option was granted on December 12, 2017. The shares underlying the option are scheduled to vest as to 25% of the shares underlying the option on October 16, 2018, with the remainder vesting in equal quarterly installments through October 16, 2021. Read SEC document |
| November 06, 2019 Filed Nov 8, 2019 17:01 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | SaleCommon Stock | 726 | $30.84 | $22,389.84 |
DisclosureSEC source: 0001562180-19-005413 · primarydocument.xml · nonDerivative · entry 9 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| November 06, 2019 Filed Nov 8, 2019 17:01 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | SaleCommon Stock | 15,740 | $29.75 | $468,260.28 |
DisclosureSEC source: 0001562180-19-005413 · primarydocument.xml · nonDerivative · entry 8 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 726 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F7 · price: This transaction was executed in multiple trades at prices ranging from $29.50 to $30.30. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 06, 2019 Filed Nov 8, 2019 17:01 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | SaleCommon Stock | 11,976 | $20.01 | $239,631.38 |
DisclosureSEC source: 0001562180-19-005413 · primarydocument.xml · nonDerivative · entry 7 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,466 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $20.00 to $20.05. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 06, 2019 Filed Nov 8, 2019 17:01 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | SaleCommon Stock | 6,188 | $19.20 | $118,838.68 |
DisclosureSEC source: 0001562180-19-005413 · primarydocument.xml · nonDerivative · entry 6 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,442 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $19.00 to $19.70. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 06, 2019 Filed Nov 8, 2019 17:01 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | SaleCommon Stock | 24,264 | $18.40 | $446,518.26 |
DisclosureSEC source: 0001562180-19-005413 · primarydocument.xml · nonDerivative · entry 5 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,630 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $18.00 to $18.98. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 06, 2019 Filed Nov 8, 2019 17:01 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | SaleCommon Stock | 4,158 | $17.59 | $73,157.93 |
DisclosureSEC source: 0001562180-19-005413 · primarydocument.xml · nonDerivative · entry 4 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,894 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $17.00 to $17.995. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 06, 2019 Filed Nov 8, 2019 17:01 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | SaleCommon Stock | 2,574 | $16.31 | $41,978.85 |
DisclosureSEC source: 0001562180-19-005413 · primarydocument.xml · nonDerivative · entry 3 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,052 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $16.00 to $16.92. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 06, 2019 Filed Nov 8, 2019 17:01 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionCommon Stock | 9,084 | $7.60 | $69,038.40 |
DisclosureSEC source: 0001562180-19-005413 · primarydocument.xml · nonDerivative · entry 2 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,626 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 06, 2019 Filed Nov 8, 2019 17:01 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionCommon Stock | 56,542 | $6.61 | $373,742.62 |
DisclosureSEC source: 0001562180-19-005413 · primarydocument.xml · nonDerivative · entry 1 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,542 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 05, 2019 Filed Nov 7, 2019 16:44 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionStock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $6.61 | $0.00 |
DisclosureSEC source: 0001562180-19-005397 · primarydocument.xml · derivative · entry 3 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,335 Underlying: Common Stock · 1,000 shares Expires 2027-12-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted on December 12, 2017. The shares underlying the option are scheduled to vest as to 25% of the shares underlying the option on October 16, 2018, with the remainder vesting in equal quarterly installments through October 16, 2021. Read SEC document |
| November 05, 2019 Filed Nov 7, 2019 16:44 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | SaleCommon Stock | 1,000 | $15.50 | $15,504.00 |
DisclosureSEC source: 0001562180-19-005397 · primarydocument.xml · nonDerivative · entry 2 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $15.50 to $15.54. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 05, 2019 Filed Nov 7, 2019 16:44 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionCommon Stock | 1,000 | $6.61 | $6,610.00 |
DisclosureSEC source: 0001562180-19-005397 · primarydocument.xml · nonDerivative · entry 1 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 07, 2019 Filed Mar 8, 2019 16:53 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | GrantStock Option (right to buy) · Derivative | 85,500 | $0.00 Strike: $8.76 | $0.00 |
DisclosureSEC source: 0000899243-19-006924 · doc4.xml · derivative · entry 1 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,500 Underlying: Common Stock · 85,500 shares Expires 2029-03-06 F1 · derivative.exercise_date: This option was granted on March 7, 2019, and the shares underlying the option vest in equal quarterly installments through March 7, 2023, subject to continued service. Read SEC document |
| January 22, 2019 Filed Jan 24, 2019 22:48 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $33.02 | $0.00 |
DisclosureSEC source: 0001104659-19-003201 · a4.xml · derivative · entry 1 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2029-01-21 F1 · derivative.exercise_date: This option was granted on January 22, 2019 and vests over one year in twelve equal monthly installments, commencing on February 22, 2019. Read SEC document |
| December 14, 2018 Filed Dec 18, 2018 13:43 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right To Buy) · Derivative | 1,167 | $0.00 Strike: $33.63 | $0.00 |
DisclosureSEC source: 0001070081-18-000085 · wf-form4_154514061932562.xml · derivative · entry 2 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,167 Underlying: Common Stock · 1,167 shares Expires 2028-12-13 Read SEC document |
| December 14, 2018 Filed Dec 18, 2018 13:43 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right To Buy) · Derivative | 14,000 | $0.00 Strike: $33.63 | $0.00 |
DisclosureSEC source: 0001070081-18-000085 · wf-form4_154514061932562.xml · derivative · entry 1 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2028-12-13 F1 · derivative.exercise_date: This option award vests in thirty-six approximately equal monthly installments, commencing on January 14, 2019 and continuing on each successive monthly anniversary of thereafter, ending on the third year anniversary of the grant date. Read SEC document |
| July 19, 2018 Filed Jul 20, 2018 17:41 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | GrantStock Option (right to buy) · Derivative | 46,811 | $0.00 Strike: $11.50 | $0.00 |
DisclosureSEC source: 0000899243-18-020282 · doc4.xml · derivative · entry 1 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,811 Underlying: Common Stock · 46,811 shares Expires 2028-07-18 F1 · derivative.exercise_date: This option was granted on July 19, 2018 and is scheduled to vest in equal quarterly installments through July 19, 2022, subject to continued service. Read SEC document |
| December 07, 2016 Filed Dec 9, 2016 17:17 UTC | PAREXEL INTERNATIONAL CORP PRXL · Entity 172709 | GrantCommon Stock | 2,348 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-16-069609 · form4.xml · nonDerivative · entry 1 Reeve Emma · CIK 0001680329 · Corp. VP & Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,468 F1 · security: Shares of restricted stock awarded pursuant to PAREXEL International Corporation 2015 Stock Incentive Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.